Viatris to divest India API, women's healthcare businesses for USD 1.2 billion
Advertisement
Viatris (formerly known as Mylan Inc) has finalised two deals in India to divest its API (active pharmaceutical ingredients) and women's healthcare businesses for a combined consideration of around $1.2 billion, the healthcare company said on Monday.
The United States-headquartered global healthcare company has centres in Pittsburgh, Shanghai, and Hyderabad. Viatris has executed an agreement to divest its API business in India to Iquest Enterprises, a Hyderabad-based pharmaceutical company owned by Nimmagadda Prasad, the founder of Matrix Laboratories.
For more details, check out the link given below:
US Pharma Giant Viatris To Divest India API, Women's Healthcare Businesses For USD 1.2 Billion
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.